Low Back Pain - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Low Back Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Low Back Pain - Pipeline Review, H1 2015', provides an overview of the Low Back Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Low Back Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Low Back Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Low Back Pain Overview 8
Therapeutics Development 9
Pipeline Products for Low Back Pain - Overview 9
Pipeline Products for Low Back Pain - Comparative Analysis 10
Low Back Pain - Therapeutics under Development by Companies 11
Low Back Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Low Back Pain - Products under Development by Companies 16
Low Back Pain - Companies Involved in Therapeutics Development 18
Aestus Therapeutics, Inc. 18
Astellas Pharma Inc. 19
Collegium Pharmaceutical, Inc. 20
Eisai Co., Ltd. 21
Eli Lilly and Company 22
Frontier Biotechnologies Co., Ltd 23
Grunenthal GmbH 24
Ipsen S.A. 25
MEDRx Co., Ltd. 26
Merck & Co., Inc. 27
Mesoblast Limited 28
Nektar Therapeutics 29
Pacira Pharmaceuticals, Inc. 30
Paladin Labs Inc. 31
Pfizer Inc. 32
Stayble Therapeutics 33
Teikoku Pharma USA, Inc. 34
Low Back Pain - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(acetaminophen + tramadol hydrochloride) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diclofenac sodium + eperisone) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(etodolac + lidocaine) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(etoricoxib + tizanidine) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
(oxycodone hydrochloride + naltrexone) ER - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AB-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
abobotulinumtoxin A - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ASP-7962 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Atx09-002 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
bupivacaine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cebranopadol - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drug for Chronic Low Back Pain - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
duloxetine hydrochloride DR - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
eperisone SR - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
flurbiprofen sodium - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MPC-06ID - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NKTR-181 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
oxycodone hydrochloride ER - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PF-06372865 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Low Back Pain - Recent Pipeline Updates 75
Low Back Pain - Dormant Projects 89
Low Back Pain - Discontinued Products 91
Low Back Pain - Product Development Milestones 92
Featured News & Press Releases 92
Apr 07, 2015: Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 92
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 92
Jan 14, 2015: Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference 93
Nov 13, 2014: Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting 94
Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin 95
Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform 96
Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 96
Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 97
Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 98
Apr 22, 2013: Mesoblast Reports Positive Interim Results In Phase II Trial Of Adult Stem Cells For Intervertebral Disc Repair 98
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Low Back Pain, H1 2015 9
Number of Products under Development for Low Back Pain - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H1 2015 18
Low Back Pain - Pipeline by Astellas Pharma Inc., H1 2015 19
Low Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2015 20
Low Back Pain - Pipeline by Eisai Co., Ltd., H1 2015 21
Low Back Pain - Pipeline by Eli Lilly and Company, H1 2015 22
Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2015 23
Low Back Pain - Pipeline by Grunenthal GmbH, H1 2015 24
Low Back Pain - Pipeline by Ipsen S.A., H1 2015 25
Low Back Pain - Pipeline by MEDRx Co., Ltd., H1 2015 26
Low Back Pain - Pipeline by Merck & Co., Inc., H1 2015 27
Low Back Pain - Pipeline by Mesoblast Limited, H1 2015 28
Low Back Pain - Pipeline by Nektar Therapeutics, H1 2015 29
Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2015 30
Low Back Pain - Pipeline by Paladin Labs Inc., H1 2015 31
Low Back Pain - Pipeline by Pfizer Inc., H1 2015 32
Low Back Pain - Pipeline by Stayble Therapeutics, H1 2015 33
Low Back Pain - Pipeline by Teikoku Pharma USA, Inc., H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Assessment by Combination Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Low Back Pain Therapeutics - Recent Pipeline Updates, H1 2015 75
Low Back Pain - Dormant Projects, H1 2015 89
Low Back Pain - Dormant Projects (Contd..1), H1 2015 90
Low Back Pain - Discontinued Products, H1 2015 91